Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer...

Area of Science:

• Oncology
• Immunology
• Biomarkers

Background:

• Immune checkpoint inhibitors (ICI) are crucial in cancer therapy.
• Limited biomarkers exist for predicting thromboembolic risk, treatment response, and survival in ICI-treated patients.
• This study investigates systemic inflammatory indices as potential biomarkers.

Purpose of the Study:

• To evaluate the association of systemic inflammatory indices with clinical outcomes in patients treated with ICI.
• To identify biomarkers for predicting venous thromboembolism (VTE) risk, overall survival (OS), and progression-free survival (PFS).

Main Methods:

• Retrospective cohort study of 580 ICI-treated patients.
• Calculated inflammatory indices: neutrophil-lymphocyte-ratio (NLR), platelet-lymphocyte-ratio (PLR), lymphocyte-monocyte-ratio (LMR), systemic immune-inflammation-index (SII), and C-reactive-protein-albumin-ratio (CAR) at ICI start and longitudinally.
• Assessed VTE risk using competing risk analysis and OS/PFS using Cox regression.

Main Results:

• Higher baseline NLR, CAR, and SII were associated with shorter OS; higher LMR was associated with longer OS.
• Elevated NLR, PLR, lower LMR, and higher CAR predicted poorer PFS.
• No baseline indices predicted VTE, but increases in PLR and CAR within 3 months were linked to higher VTE risk.

Conclusions:

• Selected inflammatory indices correlate with poor OS and PFS in ICI-treated patients.
• Longitudinal monitoring of these indices may help identify patients at increased risk for VTE.
• Further research into inflammatory biomarkers could improve patient management in ICI therapy.